Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-2129 tablet approved to conduct clinical trials for treating acute pain.
[Translation]
Hengrui Medicine (600276.SH) announced that recently, its subsidiary Shanghai Hengrui Medicine Co., Ltd. and Shandong Shengdi...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Shandong Shengdi Pharmaceutical Co., Ltd. have recently received the approval notice for drug clinical trial of HRS-2129 tablets from the National Medical Products Administration ("NMPA"). The approval allows the product to conduct clinical trials for the treatment of acute pain. According to the information available, there are currently no similar products approved for marketing both domestically and internationally.
Related Articles
Wuhan Tianyuan Group (301127.SZ) subsidiary plans to acquire 100% equity of Jiangsu Kairun Hydrogen Energy to optimize its layout.
Shentong Technology Group (605228.SH) plans to launch a restricted stock and stock option incentive plan for 2025.
ACME INTERNATIONAL HOLDINGS (01870) issued 30 million shares on December 19th according to the placement agreement.
Wuhan Tianyuan Group (301127.SZ) subsidiary plans to acquire 100% equity of Jiangsu Kairun Hydrogen Energy to optimize its layout.
Shentong Technology Group (605228.SH) plans to launch a restricted stock and stock option incentive plan for 2025.
ACME INTERNATIONAL HOLDINGS (01870) issued 30 million shares on December 19th according to the placement agreement.
